{ "symbol": "ILMN", "company": "Illumina, Inc.", "generated_at": "2026-06-24T07:36:48.764Z", "event_count": 8, "events": [ { "type": "scout_dossier", "ts": "2026-06-24T05:50:57.142Z", "summary": "Illumina is a dominant DNA sequencing platform company (92% of revenue from sequencing) that has had an extraordinary run — +77% YTD, near 52-week highs. The stock appears fully-valued at forward P/E ~28x and EV/EBITDA ~23x with modest 4.8% revenue growth. JPMorgan's recent upgrade to Overweight ($185 target vs $165 spot) is a bullish catalyst but represents only ~12% upside — insufficient for an asymmetric long setup, especially given null options chain data making any earnings-based spread strategy unreliable. The board addition of Eli Lilly's R&D Chief (Dr. Skovronsky) on June 16 is the most interesting edge: his drug-discovery and translational medicine expertise signals Illumina's deepening push into clinical genomics and multiomics markets. No material insider open-market purchases were found; one senior officer sale was observed. Given premium valuation, weak options infrastructure, and lack of a mispriced catalyst, this name fits 'range_bound_or_income' if IV were elevated — but with null bid/ask data across all strikes (fatal structure flaw), even income strategies are unsupported. Verdict: no_anomaly.", "verdict": "no_anomaly", "confidence": 4, "tool_calls": 19, "walltime_min": 36, "debug_path": "dossiers/2026-06-24-ILMN.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-06-17T04:52:55.012Z", "summary": "{\"symbol\":\"ILMN\",\"company\":\"Illumina, Inc.\",\"investigation_summary\":\"Illumina has had an extraordinary run (up ~99% over one year, +69% YTD) driven by NovaSeq X adoption acceleration, clinical sequencing demand growth, and consistent earnings beats. The Form 4 trigger was a cluster of filings — but upon reading them closely, they reveal the opposite of bullish insider conviction: Keith Meister's C", "verdict": "unparseable", "tool_calls": 22, "walltime_min": 31, "debug_path": "dossiers/2026-06-17-ILMN.scout.debug.json" }, { "type": "analyst_decision", "ts": "2026-06-10T02:32:16.969Z", "skip": true, "reason": "Heavy insider distribution ($110M sold vs $300K bought) and active anti-signals (customer concentration, dilution risk) outweigh the earnings catalyst and technical momentum. With the stock up 56% YTD at an elevated forward P/E, neither long nor income structures offer a favorable risk/reward profile.", "score": 30, "breakdown": { "smart_money": 0, "options_flow": 2, "catalyst": 18, "mispricing": 0, "quality": 0, "technical": 10 }, "debug_path": "drafts/2026-06-10-ILMN.analyst.debug.json" }, { "type": "scout_dossier", "ts": "2026-06-10T02:31:16.927Z", "summary": "The Form 4 cluster triggering this investigation is primarily driven by Keith Meister (Corvex Management) converting equity swaps into actual shares and aggressively selling them at current elevated prices — over 700,000 shares sold May-June 2026 in the $140-165 range. This is a DISTRIBUTION pattern from an activist/large holder, not a bullish accumulation signal. Separately, a SVP (Patricia Leckman) made small sales near all-time highs. Meanwhile, fundamentals are strong — Q1 2026 EPS beat by 9%, multiple oncology product launches in May-June 2026 (StrataMap Spatial Solution, fireflyGO automation platform with SPT Labtech, whole-genome WGS MRD research kit, IDT DRAGEN integration), and NovaSeq X adoption accelerating. The stock has run +56% YTD and sits within ~5% of its 52-week high ($160 vs $177). Forward P/E of 27x is elevated versus sector peers, but ILMN's dominance in sequencing justifies a premium. Earnings on July 30 could be a near-term catalyst or inflection point.", "verdict": "range_bound_or_income", "confidence": 4, "tool_calls": 22, "walltime_min": 22, "debug_path": "dossiers/2026-06-10-ILMN.scout.debug.json" }, { "type": "analyst_decision", "ts": "2026-06-05T12:14:06.010Z", "skip": true, "reason": "Massive insider distribution ($115M sold vs $2.5M bought), rich valuation at/near peak multiples, and overbought technicals (RSI 74.9) make this an unfavorable entry. The bull case is already priced in with no mispricing or asymmetric structure available.", "score": 21, "breakdown": { "smart_money": 0, "options_flow": 2, "catalyst": 15, "mispricing": 0, "quality": 0, "technical": 4 }, "debug_path": "drafts/2026-06-05-ILMN.analyst.debug.json" }, { "type": "scout_dossier", "ts": "2026-06-05T12:13:32.607Z", "summary": "Illumina is a dominant sequencing and array-based genomics platform company ($25B market cap) that has surged ~84% YTD to within 5% of its all-time high. Q1 FY2026 results beat on both EPS (+9% surprise at $1.15 vs $1.055 est.) and revenue, driven by NovaSeq X adoption acceleration, clinical sequencing demand, and early SomaLogic proteomics contribution following the January 2026 acquisition for ~$460M cash + contingent consideration. The stock is richly valued (forward P/E 28.4x, EV/EBITDA 23x) with elevated RSI at 74.9 into a July 30 earnings report that historically beats by 9-18%. Keith Meister's Corvex Capital remains a large shareholder but has been aggressively distributing shares into this rally. The stock lacks the mispricing element — it is fully valued at/near peak multiples, making any new long entry asymmetric-risk-unfavorable. However, with IV elevated from recent volatility and the stock range-bound near 52w high, income strategies (CC/strangle) are structurally viable.", "verdict": "range_bound_or_income", "confidence": 4, "tool_calls": 18, "walltime_min": 31, "debug_path": "dossiers/2026-06-05-ILMN.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-29T10:06:26.064Z", "summary": "{\"symbol\":\"ILMN\",\"company\":\"Illumina, Inc.\",\"investigation_summary\":\"Illumina is a dominant sequencing platform company with strong NovaSeq X momentum and recently raised FY2026 guidance after a Q1 earnings beat. However, the stock has run ~54% YTD to fresh 52-week highs at RSI 76, leaving it fully valued on forward P/E (~26.8x) vs a sector where 20-24x is more typical for compounder names without", "verdict": "unparseable", "tool_calls": 20, "walltime_min": 32, "debug_path": "dossiers/2026-05-29-ILMN.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-22T11:04:45.941Z", "summary": "Illumina is a fundamentally strong sequencing platform company (FY2025 revenue $4.39B, ~68% gross margins) that has recovered sharply (+52% YTD from September lows) following Q1 2026 earnings beats and raised guidance with an expanded buyback. The Form 4 cluster triggering this investigation was Keith Meister / Corvex converting equity swaps into actual shares then aggressively SELLING those shares at $144-$148 in May 2026 — not a bullish accumulation signal, but rather a distribution pattern from a large stakeholder who holds ~3.5M remaining shares. The stock is near its 52-week high with elevated RSI (63) and no meaningful pullback in over two months of grinding higher.", "verdict": "no_anomaly", "confidence": 4, "tool_calls": 19, "walltime_min": 26, "debug_path": "dossiers/2026-05-22-ILMN.scout.debug.json" } ], "lessons": [], "chart_signal": { "ticker": "ILMN", "call": "HOLD", "confidence": 3, "score": 4, "factors": { "above_200dma": "+2", "above_50dma": "+1", "momentum_strong_up": "+2 (58.2%)", "rsi_neutral": "0 (59.5)", "recent_macd_bearish_cross": "-2 (6d ago)", "near_52w_high": "+1 (-3.5% from high)" }, "summary": "HOLD (score +4) · 12-1 mom 58.2% · RSI 59.5 · above_both · -3.5% from high", "last_close": 164.93, "one_month_ago_close": 144.83, "twelve_month_ago_close": 91.52, "twelve_one_momentum_pct": 58.25, "rsi_14": 59.5, "ma_stack": "above_both", "from_period_high_pct": -3.51, "period_high": 170.93, "price_targets": { "bear": 95, "fair": 153.65, "bull": 196.57, "bear_return_pct": -42.4, "fair_return_pct": -6.8, "bull_return_pct": 19.2, "method": "street_targets ⨯ chart_floors", "street": { "target_low": 95, "target_mean": 149.83333, "target_high": 185, "analyst_count": 18 } }, "generated_at": "2026-06-24T07:36:48.760Z" } }